Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Dirk Schadendorf, ESMO 2018 – Encorafenib plus Binimetinib for BRAF-mutant Metastatic Melanoma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 15th 2018

In this interview, filmed at ESMO 2018, Professor Schadendorf discusses the use of encorafenib plus binimetinib for BRAF-mutant metastatic melanoma.

Questions:

1. Could you tell us a little about the efficacy and safety findings of the COLUMBUS study that have led to the recent European approval of encoranefib plus binimetanib for BRAF-mutant metastatic melanoma? (0:11)

2. What are the advantages of this combination compared with other combined BRAF/MEK inhibitor therapies? (1:25)

3. What are the best treatment options for patients whose disease progresses on this therapy? (2:41)

4. How can we prevent or overcome resistance to BRAF/MEK inhibitors? (3.18)

5. How is the approval of this combined therapy likely to impact on clinical practice? (4:24)

Speaker disclosures: Dirk Schadendorf has nothing to disclose in relation to this interview.

Filmed at the European Society for Medical Oncology (ESMO) congress, Germany, 19–23 October 2018

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup